Taglich Brothers Initiates Coverage on Cardium Therapeutics, Inc.

NEW YORK, October 22, 2007 – Taglich Brothers, Inc. announces it initiated coverage of Cardium Therapeutics, Inc. (AMX: CXM).

Cardium Therapeutics, Inc., headquartered in San Diego, CA, is a biomedical company that is developing regenerative therapies for the treatment of myocardial ischemia and diabetic foot ulcers. The company’s surface and endovascular temperature modulation systems, which are already commercialized, have applications in neurosurgery, cardiac arrest, stroke and central nervous system trauma cases. Potentially wide selling products are being developed or commercialized with a view to offering them for acquisition to large pharmaceutical or biomedical firms. The lead pipeline product, Generx, aims to reverse microvascular ischemia by promoting angiogenesis. A second pipeline product, Excellarate, is a wound care product developed to heal diabetic foot ulcers that are not responsive to standard treatments. Temperature modulation systems, a product line already commercialized, are helpful in treating neurosurgery, cardiac arrest, stroke and central nervous system trauma patients.

The complete 20-page report is available at www.taglichbrothers.com.

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the Company mentioned in this report: All research issued by Taglich Brothers, Inc. is based on public information. The company paid a $5,000 (USD) engagement fee in August, 2007 and will, commencing upon distribution of our initial report, pay $1,750 (USD) per month for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.